The AP4M1 knockout A-549 polyclonal cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the AP4M1 gene has been disrupted. This polyclonal product provides a heterogeneous pool of cells bearing various loss-of-function alleles at the target locus, enabling robust functional studies without single-cell clonal selection. The knockout model is designed for investigations into AP4M1-dependent protein trafficking and autophagy in a human lung adenocarcinoma background.
The A-549 host cell line is an established epithelial cell model derived from human lung adenocarcinoma tissue of a 58-year-old Caucasian male. Widely employed in cancer biology and drug discovery, A-549 cells exhibit characteristic properties of lung adenocarcinoma, including rapid proliferation and responsiveness to oncogenic signals. Their epithelial nature and well-characterized genetic background make them particularly suitable for studying cargo sorting pathways and autophagy in the context of non-small cell lung cancer.
AP4M1 encodes the mu subunit of the adaptor protein complex 4 (AP-4), a heterotetrameric complex that also comprises AP4E1, AP4B1, and AP4S1. The AP-4 complex mediates selective transport of cargo proteins from the trans-Golgi network to endosomes and autophagosomes, with AP4M1 serving as the cargo-recognition subunit. AP4M1 directly interacts with ATG9A, a core autophagy protein, and with Tepsin, an accessory factor. Upstream regulation involves serine/threonine kinases such as AMPK, which phosphorylate AP-4 components to modulate trafficking. Downstream, AP4M1-dependent sorting influences the localization of LDL receptor-related proteins and neuronal development proteins, linking AP-4 function to both metabolic and neurodevelopmental processes.
Knockout of AP4M1 in A-549 cells creates a valuable model for dissecting the role of AP-4-mediated trafficking in lung cancer biology. Disruption of this pathway may alter autophagic flux, endosomal dynamics, and surface receptor distribution, potentially affecting tumor cell growth, metastasis, and drug sensitivity. Moreover, given the association of AP4M1 mutations with hereditary spastic paraplegia and intellectual disability, this cell model offers a simplified system to interrogate the cellular mechanisms underlying these neurological disorders, despite its non-neuronal origin.
Researchers can employ these polyclonal knockout cells in a variety of assays to probe AP4M1 function. Western blotting and immunofluorescence enable verification of AP4M1 loss and visualization of disrupted protein localization. Autophagy flux assays, such as LC3 turnover measurement or p62 degradation, directly assess the impact on autophagy. Co-immunoprecipitation experiments facilitate mapping of AP-4 complex interactions, while RT-qPCR provides insights into transcriptional responses. These applications support studies ranging from fundamental cell biology to disease-specific investigations. For further information or assistance, please contact Ascent Research.
